What is the translation of " NUSPOJAVA VIDJETI " in English?

• adverse reactions see
• adverse events see

Examples of using Nuspojava vidjeti in Croatian and their translations into English

Za zbrinjavanje nuspojava vidjeti dio 4.4 i 4.8.
For management of adverse reactions, see sections 4.4 and 4.8.

Izostanak udarne doze može smanjiti rizik od nuspojava vidjeti dio 5.1.
Omission of the loading dose may decrease the risk of adverse events see section 5.1.

Uzimanje Atriple s hranom može povećati izloženost efavirenzu(vidjeti dio 5.2) te može dovesti do povećane učestalosti nuspojava vidjeti dio 4.8.
The administration of Atripla with food may increase efavirenz exposure(see section 5.2) and may lead to an increase in frequency of adverse reactions see section 4.8.

Potrebno liječenje ovisi o prirodi i težini nuspojava vidjeti također“Upozorenja i mjere opreza”.
The treatment required depends on the nature and severity of side-effects see also“Warnings and precautions”.

Ispitanici s visokim početnim CPT rezultatom imali su veći rizik od razvoja ozbiljnih nuspojava vidjeti dio 4.4.
Subjects with a high baseline CPT score were at higher risk of developing serious adverse events see section 4.4.

Pravilna primjena će smanjiti pojavu takvih nuspojava vidjeti odjeljak 4.9.
Correct application will minimise the occurrence of such events see section 4.9.

Veća je vjerojatnost da će u bolesnika ≥ 75 godina biti potrebno smanjenje doze radi zbrinjavanja nuspojava vidjeti dio 5.2.
Patients≥75 years may be more likely to require dose reduction to manage adverse effects see section 5.2.

SIMBRINZA se ne smije primjenjivati kod djece zbog mogućnosti ozbiljnih nuspojava Vidjeti dio 3.
SIMBRINZA should not be used in children due to the potential for serious side effects see section 3.

Kontraindicirana zbog povećanog rizika od ergotizma i drugih ozbiljnih vazospastičnih nuspojava vidjeti dio 4.3.
Contraindicated due to the increased risk of ergotism and other serious vasospastic adverse events see section 4.3.

U bolesnika s klinički značajnim oštećenjem bubrega ili jetre može se razviti više nuspojava vidjeti dijelove 4.2 i 5.2.
Patients with clinically significant renal or hepatic impairment might experience more adverse reactions see sections 4.2 and 5.2.

Oštećenje bubrega: Bolesnici s klinički značajnim oštećenjem bubrega mogli bi osjetiti više nuspojava vidjeti dio 4.2 i 5.2.
Renal impairment: Patients with clinically significant renal impairment might experience more adverse reactions see sections 4.2 and 5.2.

Oštećenje jetre: Bolesnici s klinički značajnim oštećenjem jetre mogli bi osjetiti više nuspojava vidjeti dijelove 4.2 i 5.2.
Hepatic impairment: Patients with clinically significant hepatic impairment might experience more adverse reactions see sections 4.2 and 5.2.

Ne preporučuje se istovremena primjena Vireada i didanozina, jer to može rezultirati povećanim rizikom od nuspojava vidjeti dio 4.5.
Co-administration of Viread and didanosine is not recommended as this may result in an increased risk of adverse reactions see section 4.5.

Primjena efavirenza uz hranu može povećati izloženost efavirenzu i voditi ka povećanju učestalosti nuspojava vidjeti dio 4.4.
The administration of efavirenz with food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions see section 4.4.

Povišene koncentracije efavirenza nakon njegove primjene s hranom mogu povećati učestalost nuspojava vidjeti dijelove 4.4 i 5.2.
The increased efavirenz concentrations observed following administration with food may lead to an increase in frequency of adverse reactions see sections 4.4 and 5.2.

Primjena lijeka efavirenz uz hranu može povećati izloženost efavirenzu i dovesti do povećanja učestalosti nuspojava vidjeti dio 4.4.
The administration of efavirenz with food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions see section 4.4.

Ukupna dnevna doza iznad 100 mg/kg tjelesne težine se ne preporučuje zbog potencijalnog povećanog rizika od nuspojava vidjeti dijelove 4.4, 4.8, i 4.9.
A total daily dose above 100 mg/kg body weight is not recommended because of the potentially increased risk of adverse reactions see sections 4.4, 4.8, and 4.9.

Primjena Efavirenza Teva s hranom može povećati izloženost efavirenzu(vidjeti dio 5.2) i povećati učestalost nuspojava vidjeti dio 4.8.
The administration of Efavirenz Teva with food may increase efavirenz exposure(see section 5.2) and may lead to an increase in the frequency of adverse reactions see section 4.8.

Bolesnici s tjelesnom težinom manjom od 50 kg mogu imati više nuspojava te je vjerojatnije da će prekinuti liječenje zbog nuspojava vidjeti dio 4.2.
Patients with body weight below 50 kg may experience more adverse reactions and may be more likely to discontinue due to adverse reactions see section 4.2.

Pse treba pažljivo nadzirati te stručno procijeniti potreba za smanjenjem doze u slučaju mogućih značajnih nuspojava vidjeti poglavlje 4.5.
Dogs should be monitored carefully and professional judgement should be used to determine the need for dose reduction in the event of possible significant adverse reactions see section 4.5.

Ova se klinička procjena mora temeljiti na težini prethodne reakcije i odgovoru na primijenjeno liječenje nuspojava vidjeti dio 4.2.
This clinical assessment should be based on the severity of the preceding reaction and response to administered treatment for the adverse reaction see section 4.2.

Međutim, sistemski kortikosteroidi ili drugi imunosupresivi mogu se koristiti nakon uvođenja pembrolizumaba za liječenje imunološki uzrokovanih nuspojava vidjeti dio 4.4.
However, systemic corticosteroids or other immunosuppressants can be used after starting pembrolizumab to treat immune-related adverse reactions see section 4.4.

Povišene koncentracije efavirenza zapažene nakon primjene lijeka STOCRIN uz hranu mogu povećati učestalost nuspojava vidjeti dijelove 4.4 i 5.2.
The increased efavirenz concentrations observed following administration of STOCRIN with food may lead to an increase in frequency of adverse reactions see sections 4.4 and 5.2.

Preporučuje se uzimanje Atriple na prazan želudac jer hrana može povećati izloženost efavirenzu i može dovesti do povećane učestalosti nuspojava vidjeti dio 4.4 i 4.8.
It is recommended that Atripla be taken on an empty stomach since food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions see sections 4.4 and 4.8.

Bolesnici s kroničnim hepatitisom B ili C liječeni kombiniranom antiretrovirusnom terapijom imaju povećan rizik od teških i potencijalno smrtonosnih jetrenih nuspojava vidjeti dio 4.8.
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions see section 4.8.

Stiripentol je inhibitor enzima CYP2C19, CYP3A4 i CYP2D6 i može znatno povećati koncentracije u plazmi tvari koje se metaboliziraju ovim enzimima i povećati rizik od nuspojava vidjeti dio 4.5.
Stiripentol is an inhibitor of the enzymes CYP2C19, CYP3A4 and CYP2D6 and may markedly increase the plasma concentrations of substances metabolised by these enzymes and increase the risk of adverse reactions see section 4.5.

Potreban je oprez prilikom primjene lijeka HETLIOZ u kombinaciji s fluvoksaminom ili drugim jakim CYP1A2 inhibitorima zbog mogućeg velikog povećanja izloženosti tazimelteonu i većeg rizika od nuspojava vidjeti dio 4.5.
Caution should be used when administering HETLIOZ in combination with fluvoxamine or other strong CYP1A2 inhibitors because of a potentially large increase in tasimelteon exposure and greater risk of adverse reactions see section 4.5.

Istovremena primjena Stribilda i lijekova koje prvenstveno metabolizira CYP3A ili CYP2D6, ili koji su supstrati P-gp, BCRP, OATP1B1 ili OATP1B3 može za posljedicu imati povećane koncentracije tih lijekova u plazmi, što može uzrokovati povećanje ili produljenje njihova terapijskog učinka i nuspojava vidjeti„Kontraindicirana istodobna primjena” i dio 4.3.
Co-administration of Stribild with medicinal products that are primarily metabolised by CYP3A or CYP2D6, or are substrates of P-gp, BCRP, OATP1B1 or OATP1B3 may result in increased plasma concentrations of those products, which could increase or prolong their therapeutic effect and adverse reactions see Concomitant use contraindicated and section 4.3.

Imunološki uzrokovane nuspojave vidjeti dio 4.4.
Immune-related adverse reactions see section 4.4.

Mučnina i povraćanje bile su često prijavljene gastrointestinalne nuspojave vidjeti dio 4.8.
Nausea and vomiting were frequently reported gastrointestinal adverse reactions see section 4.8.